在患有早期帕金森病的受试者中对c-Abl抑制剂vodobatinib的评估:第二阶段,随机,双盲,安慰剂控制的研究
Harini Sarva1, Rajesh Pahwa2, Jorge Hernandez-Vara3
1Parkinson's Disease & Movement Disorders Institute, Weill Cornell Medicine, New York, NY, USA.
NPJ Parkinson's disease
|February 3, 2026
概括
伏多巴丁尼布是一种c-Abl抑制剂,在早期帕金森病 (PD) 患者中没有显示出有效性. 这种药物导致了高戒断率和增加神经纤维光链,表明潜在的危害.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,其特征是多巴胺基神经元损失.
- 在临床前的PD模型中,通过减少α-synuclein聚合,抑制cAbl氨酸激酶已经显示出有前途.
- 伏多巴丁尼布是一种穿透大脑的c-Abl抑制剂,研究其在PD中的治疗潜力.
研究的目的:
- 评估vodobatinib在早期帕金森病 (PD) 患者的疗效和安全性.
- 评估伏多巴丁尼布对疾病进展的影响,用MDS-UPDRS Part III评分进行测量.
- 为了研究伏多巴丁尼布对血清神经丝光链的影响,作为生物标志物.
主要方法:
- 第二阶段,随机,双盲,安慰剂控制的PROSEEK研究.
- 513名早期PD参与者每天接受伏多巴丁尼布 (384mg或192mg) 或安慰剂.
- 主要终点:40周MDS-UPDRS第三部分得分的变化;次要:血清神经丝光链.
主要成果:
- 观察到高,与剂量相关的早期参与者戒断率.
- 伏多巴丁尼布组与安慰剂组之间的比较有利于安慰剂运动功能.
- 在两组Vodobatinib中,血清神经丝光链的显著增加.
结论:
- 伏多巴丁尼布在治疗早期帕金森病方面表现出无效.
- 由于高戒断率和生物标志物变化,该药物的安全性概况令人担忧.
- 对PD的c-Abl抑制剂的进一步研究可能需要不同的治疗策略.
相关概念视频
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
252
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
252
01:24Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
01:24Parkinson Disease ll: Pathophysiology
34
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
34